Literature DB >> 22116143

Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy.

Charles M Bark, Bonnie A Thiel, John L Johnson.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22116143      PMCID： PMC3264180          DOI： 10.1128/JCM.06193-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  7 in total

1.  Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.

Authors:  Marc Weiner; Thomas J Prihoda; William Burman; John L Johnson; Stefan Goldberg; Nesri Padayatchi; Paula Duran; Melissa Engle; Grace Muzanye; Roy D Mugerwa; A Willem Sturm
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

2.  [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy].

Authors:  V R Aber; A J Nunn
Journal:  Bull Int Union Tuberc       Date:  1978-12

3.  Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.

Authors:  A C Hesseling; G Walzl; D A Enarson; N M Carroll; K Duncan; P T Lukey; C Lombard; P R Donald; K A Lawrence; R P Gie; P D van Helden; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2010-05       Impact factor: 2.373

4.  Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures.

Authors:  C M Bark; A Okwera; M L Joloba; B A Thiel; J G Nakibali; S M Debanne; W H Boom; K D Eisenach; J L Johnson
Journal:  Tuberculosis (Edinb)       Date:  2011-02-25       Impact factor: 3.131

5.  Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment.

Authors:  M Zierski; E Bek; M W Long; D E Snider
Journal:  Am Rev Respir Dis       Date:  1980-12

6.  Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting.

Authors:  C Pheiffer; N M Carroll; N Beyers; P Donald; K Duncan; P Uys; P van Helden
Journal:  Int J Tuberc Lung Dis       Date:  2008-07       Impact factor: 2.373

7.  Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

Authors:  John L Johnson; David Jamil Hadad; Reynaldo Dietze; Ethel Leonor Noia Maciel; Barrett Sewali; Phineas Gitta; Alphonse Okwera; Roy D Mugerwa; Mary Rose Alcaneses; Maria Imelda Quelapio; Thelma E Tupasi; Libby Horter; Sara M Debanne; Kathleen D Eisenach; W Henry Boom
Journal:  Am J Respir Crit Care Med       Date:  2009-06-19       Impact factor: 21.405
  7 in total
  8 in total

1.  A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community.

Authors:  H D Geldenhuys; A Whitelaw; M D Tameris; D Van As; K K A Luabeya; H Mahomed; G Hussey; W A Hanekom; M Hatherill
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-15       Impact factor: 3.267

2.  Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid.

Authors:  Grant Theron; Jonny Peter; Richard Meldau; Hoosain Khalfey; Phindile Gina; Brian Matinyena; Laura Lenders; Gregory Calligaro; Brian Allwood; Gregory Symons; Ureshnie Govender; Mashiko Setshedi; Keertan Dheda
Journal:  Thorax       Date:  2013-06-29       Impact factor: 9.139

3.  Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?

Authors:  Jean-Philippe Lanoix; Richard E Chaisson; Eric L Nuermberger
Journal:  Clin Infect Dis       Date:  2015-11-01       Impact factor: 9.079

4.  Correlation of mycobacterium tuberculosis specific and non-specific quantitative Th1 T-cell responses with bacillary load in a high burden setting.

Authors:  Grant Theron; Jonny Peter; Laura Lenders; Richard van Zyl-Smit; Richard Meldau; Ureshnie Govender; Keertan Dheda
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

5.  Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.

Authors:  Nathella P Kumar; Kadar Moideen; Arul Nancy; Vijay Viswanathan; Kannan Thiruvengadam; Shanmugam Sivakumar; Syed Hissar; Dina Nair; Vaithilingam V Banurekha; Hardy Kornfeld; Subash Babu
Journal:  JAMA Netw Open       Date:  2020-12-01

6.  Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and inhibition, for TB diagnosis using specimens from different body compartments.

Authors:  Grant Theron; Jonny Peter; Greg Calligaro; Richard Meldau; Colleen Hanrahan; Hoosain Khalfey; Brian Matinyenya; Tapuwa Muchinga; Liezel Smith; Shaheen Pandie; Laura Lenders; Vinod Patel; Bongani M Mayosi; Keertan Dheda
Journal:  Sci Rep       Date:  2014-07-11       Impact factor: 4.379

7.  Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa.

Authors:  Fenella Beynon; Grant Theron; Durval Respeito; Edson Mambuque; Belen Saavedra; Helder Bulo; Sergi Sanz; Keertan Dheda; Alberto L Garcia-Basteiro
Journal:  Sci Rep       Date:  2018-03-26       Impact factor: 4.379

8.  Distinct serum biosignatures are associated with different tuberculosis treatment outcomes.

Authors:  Katharina Ronacher; Novel N Chegou; Léanie Kleynhans; Joel F Djoba Siawaya; Nelita du Plessis; André G Loxton; Elizna Maasdorp; Gerard Tromp; Martin Kidd; Kim Stanley; Magdalena Kriel; Angela Menezes; Andrea Gutschmidt; Gian D van der Spuy; Robin M Warren; Reynaldo Dietze; Alphonse Okwera; Bonnie Thiel; John T Belisle; Jacqueline M Cliff; W Henry Boom; John L Johnson; Paul D van Helden; Hazel M Dockrell; Gerhard Walzl
Journal:  Tuberculosis (Edinb)       Date:  2019-08-12       Impact factor: 3.131
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.